Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 29 ... transient gene silencing, which means that they didn't make lasting changes to the DNA of a mosquito. Now, Dimopoulos and his team are using genetic modification (GM) to ... malaria because different tactics will work in different scenarios. In some places, a vaccine may work best, in more remote places, other low cost, low tech approaches will work ...
2009 NOV 16 ... Urocidin™ is a patented formulation of Mycobacterial Cell Wall-DNA Complex (MCC) developed by Bioniche for the treatment of non-muscle-invasive bladder ... for the Company's Urocidin™ bladder cancer therapy and the E. coli O157 cattle vaccine development program. This expense line will increase going forward with the start of the ...
2009 NOV 16 ... of therapeutic cancer vaccines based on its patented ImmunoBody® platform, SCIB1 DNA vaccine has been successfully completed ahead of the planned clinical trials that are expected ...
2009 NOV 16 ... Cyto Pulse Sciences, a leading producer of electric field based, intradermal DNA Vaccine delivery systems, announced approval by the Swedish regulatory authorities to begin a ...
2009 NOV 16 ... with infinite possibilities," write Frist and Sezibera. "Hearts are transplanted, DNA is decoded, and new medical advances are made every day. Yet we continue to be stymied ... (pneumococcal disease) and Haemophilus influenzae type b (Hib). However, use of Hib vaccine has only recently expanded to low-income countries and pneumococcal vaccine is not yet ...
Subject: The Global Coalition against Child Pneumonia
2009 NOV 23 ... States, Biotechnology, Breast Cancer, Breast Carcinoma, Cancer Vaccines, Chemotherapy, DNA Research, DNA Vaccines, Drug Therapy, Immunization, Immunology, Immunotherapy, Medical ... is an increasing need to optimize cancer management and therapy to elderly patients. Vaccine therapy for cancer is less toxic than chemotherapy or radiation and could be, therefore, ...
2009 NOV 16 ... bodies. This machinery is used during envelopment of many RNA viruses and some DNA viruses, including herpes simplex virus type 1. Other viruses mature independent of ... develop in CMV-infected cells," wrote R. Tandon and colleagues, Emory University, Emory Vaccine Center. The researchers concluded: "Thus, ESCRT machinery is involved in ...
2009 NOV 23 ... WSSV. The result showed that the groups treated with IgY from inactivated WSSV and DNA vaccine were, respectively, 20% and 80% mortality, which were significant difference in survival ...
2009 NOV 23 ... plasmid. BALB/c mice were immunized with LipL32 and recombined LipL32-41-OmpL1 using DNA-DNA, DNAprotein and protein-protein strategies, respectively," scientists in Shanghai, ... with the pVAX1 control group. The groups receiving the recombined LipL3241- OmpL1 vaccine induced anti-LipL41 and anti-OmpL1 antibodies and yielded better splenocyte ...
2009 NOV 16 ... tcpA, zot, toxR, toxS, toxT, and ace by polymerase chain reaction." "DNA sequences of ctxA, tcpA, zot and toxR also were investigated in 8 selected isolates. the ... information for facilitating future studies on the development and design of appropriate vaccine providing protection against local strains." Kondo and colleagues ...
2009 NOV 23 ... for the prevention of hCMV infection and disease, is a poloxamer-formulated, bivalent DNA vaccine that contains plasmids encoding hCMV tegument phosphoprotein 65 and the major hCMV ...
2009 NOV 16 ... Republic of China report. "Cervical cell samples were analysed for HPV DNA by a MY09/11-based PCR assay. Human papillomavirus prevalence was 6.7% overall and 4.8% ... prevalent HPV types in Beijing, indicating the potential for the prophylactic HPV 16/18 vaccine in China." Zhao and colleagues published their study in British Journal of ...
2009 NOV 23 ... virus, because of its small size and high cleavage activity, to generate an efficient TB DNA vaccine (V-2A). V-2A expresses three mycobacterial antigens, Rv3407, Ag85A, and HspX, in a ...
2009 NOV 23 ... was conducted at regular intervals. Cervical and anogenital swabs were collected for HPV DNA testing. Examination for the presence of vulvar and vaginal lesions was also done. ... "Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection from HPV 6/11/16/18-related cervical, vaginal, and ...
2009 NOV 16 ... synergies." "Here we studied the anti-tumor effects of combining plasmid DNA (pDNA) vaccination and anti-angiogenesis in B16F10 murine model. By using ... published the results of their research in Oncology Reports (Enhancement of DNA cancer vaccine efficacy by combination with anti-angiogenesis in regression of established subcutaneous ...
2009 NOV 23 ... in Human & Experimental Toxicology (Toxicology and biodistribution study of CIGB-230, a DNA vaccine against hepatitis C virus. Human & Experimental Toxicology, 2009;28(8):479-491). ...
2009 NOV 16 ... What scientists did not know is how the innate immune system is propelled to react to DNA-based microbes. Armed with the knowledge that STING triggers interferon in basic cells, ... reacts the same way," says Barber. The theory is that without STING, a DNA-based vaccine wouldn't have the effectiveness because the body would not create interferon and other ...
2009 NOV 23 ... patent application on novel technology for the detection of Human Papilloma Virus (HPV) DNA, based on Xenomics transrenal DNA technology. The technology would be applied to ... rapid growth based upon more market awareness after the introduction of the HPV vaccine, Gardasil®, which was developed by Merck & Co. (NYSE: MRK). The ...
